Although our data confirm that constitutive expression of DUX4c may have a detrimental effect on terminal myogenic differentiation (Knopp et al., 2016), the therapeutic potential of DUX4c re-expression in FSHD muscle warrants further investigation. Here, DUX4L9 is linked to facioscapulohumeral muscular dystrophy.